Identifying and Solving Top Challenges to Oncology Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. David Rimm and Roy Herbst identify the top challenges in the area of biomarker testing as well as solutions to these challenges, including availability of sufficient tissue for a large number of biomarker assays, the time some biomarker tests require for completion, the need for a tight association of test results with clinical outcomes, and the development of companion diagnostics for certain immunotherapies.
Dr Sibylle Loibl explains how fulvestrant (with or without palbociclib) fits in the treatment paradigm for patients with HR+/ HER2-negative metastatic breast cancer.
Dr. S. Yosuf Zafar has found that out of pocket costs impact patient well-being, quality of life, and quality of care. He stresses that costs need to be reduced in order to provide the best medical treatment for all patients.